Alkermes plc (NASDAQ:ALKS) stock identified change of 12.86% away from 52-week low price and recently located move of -49.32% off 52-week high price. It has market worth of $3.02B. ALKS stock has been recorded -3.57% away from 50 day moving average and -11.27% away from 200 day moving average. Moving closer, we can see that shares have been trading 3.27% off 20-day moving average.
On Jan. 6, 2020, Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company’s fourth quarter and year-end 2019 financial results. Management will also discuss financial expectations for 2020 and provide an update on the company.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a clinical pipeline of product candidates for diseases that include schizophrenia, depression, addiction, multiple sclerosis, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
The Healthcare sector company, Alkermes plc noticed change of -1.39% to $19.13 along volume of 2353088 shares in recent session compared to an average volume of 1.61M. The stock observed return of 9.56% in 5 days trading activity. The stock was at 0.05% over one month performance. ALKS’s shares are at -5.06% for the quarter and driving a -41.12% return over the course of the past year and is now at -6.23% since this point in 2018.
The average volatility for the week at 5.60% and for month was at 4.19%. There are 157.97M shares outstanding and 156.23M shares are floated in market. Right now the stock beta is 1.93.